COPENHAGEN, Nov 30 (Reuters) - Danish biotechnology firm Bavarian Nordic (BAVA.CO) aims to seek approval next year to sell its smallpox vaccine Imvamune in Canada, which would be its first market, the company said on Monday.
The New Drug Submission for Imvamune is expected to be filed in the second half of 2010, which could lead to the first licence for the drug in 2011, Bavarian Nordic said in a statement.
Chief Executive Anders Hedegaard said the strategy was to obtain regulatory approval for Imvamune as a vaccine for the general population, including those for whom traditional vaccines are not suited.
(Reporting by John Acher; editing by John Stonestreet)
email@example.com; +45 2630 9650; Reuters Messaging: firstname.lastname@example.org